Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma

N/AEnrolling By InvitationNCT07713901

Novo Nordisk A/S93,600,000 enrolled

Overview

This is a database linkage study utilizing real-world data (RWD) to determine whether certain medicines used to treat type 2 diabetes (T2D) and support weight management (called GLP-1 RAs (Glucagon-like peptide-1 receptor agonists )) are linked to an increased risk of a rare cancer called medullary thyroid carcinoma (MTC). The purpose of this study is to compare how often medullary thyroid cancer occurs in people taking these medicines versus those taking other similar treatments. This study will use dispensed prescription claims and State Cancer Registry data to assess the risk of MTC.

Study Type

OBSERVATIONAL

Enrollment

93,600,000

Conditions

Medullary Thyroid Carcinoma

Interventions

No treatment givenOTHER

No treatment given

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * 18 years or older during the year of index (date of qualifying medication) * In addition to index medication, greater than or equal to (≥) 1 dispensed medication (any class) within 24 months prior to the index date1 * ≥1 dispensed medication (any class) after the index date and within 12 months of index date (12-month post-index period) * No evidence of cohort qualifying medication during 12-month before the index date * Reside in the US, including the District of Columbia (DC) during the study period * No missing values for year of birth Exclusion Criteria: * Patients with a diagnosis of MTC in the linked SCR data before their index date will not be included in the study.

Database Linkage Study to Evaluate the Risk of Medullary Thyroid Carcinoma

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes